Literature DB >> 8657761

Repair of calvarial defects with flap tissue: role of bone morphogenetic proteins and competent responding tissues.

R K Khouri1, D M Brown, B Koudsi, E G Deune, L A Gilula, B C Cooley, A H Reddi.   

Abstract

Bone morphogenetic proteins 2 through 8 have the ability to induce the in vivo transformation of extraskeletal mesenchymal tissue into bone. The aims of this investigation were to determine the optimal responding tissue and the specificity of the inductive effect of bone morphogenetic protein 3. The optimal responding tissue was found to be skeletal muscle. The specificity of this response to bone morphogenetic protein 3 was compared with that of recombinant human basic fibroblast growth factor, recombinant platelet-derived growth factor, and recombinant insulin-like growth factor. Bone morphogenetic protein 3 was the only factor that induced de novo bone formation. This ability to transform muscle into bone was tested in 7 x 7 mm irradiated skull defects in the rat. After 1500 rads of exposure, these defects showed no significant signs of healing by 8 months. When these defects were treated with the microvascular transfer of a nonirradiated muscle flap, they had 8 percent healing at 4 months and 37 percent healing by 8 months. Defects treated with 30 micrograms bone morphogenetic protein 3 (without the muscle flap) achieved 50 percent healing by 4 months and 64 percent healing by 8 months. When the defects were treated with both the muscle flap and bone morphogenetic protein 3, there was 96 percent healing by 4 months and 100 percent healing by 8 months (p < 0.015, compared with bone morphogenetic protein 3 alone at both time points). At 8 months, the transplanted muscle was entirely transformed into bone and healed the skull defect with newly generated bone indistinguishable from the surrounding calvarial tissue. These findings suggest a potential clinical utility of bone morphogenetic protein 3-induced bone formation in skeletal reconstructions. Furthermore, they also show that there is a collaborative requirement for both the osteoinductive factor bone morphogenetic protein 3 and the presence of competent responsive cells in the well-perfused muscle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657761     DOI: 10.1097/00006534-199607000-00017

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  6 in total

Review 1.  Craniofacial tissue engineering by stem cells.

Authors:  J J Mao; W V Giannobile; J A Helms; S J Hollister; P H Krebsbach; M T Longaker; S Shi
Journal:  J Dent Res       Date:  2006-11       Impact factor: 6.116

2.  DBM induced ectopic bone formation in the rat: the importance of surface area.

Authors:  C C Schouten; Ed H M Hartman; P H M Spauwen; J A Jansen
Journal:  J Mater Sci Mater Med       Date:  2005-02       Impact factor: 3.896

3.  Bone regeneration in defects compromised by radiotherapy.

Authors:  W-W Hu; B B Ward; Z Wang; P H Krebsbach
Journal:  J Dent Res       Date:  2010-01       Impact factor: 6.116

4.  Mandibular reconstruction using an axially vascularized tissue-engineered construct.

Authors:  Ahmad M Eweida; Ayman S Nabawi; Mona K Marei; Mohamed R Khalil; Habashi A Elhammady
Journal:  Ann Surg Innov Res       Date:  2011-03-20

5.  Investigating the Vascularization of Tissue-Engineered Bone Constructs Using Dental Pulp Cells and 45S5 Bioglass® Scaffolds.

Authors:  Reem El-Gendy; Jennifer Kirkham; Phillipa J Newby; Yamuna Mohanram; Aldo Roberto Boccaccini; Xuebin B Yang
Journal:  Tissue Eng Part A       Date:  2015-04-29       Impact factor: 3.845

6.  Myoblast sensitivity and fibroblast insensitivity to osteogenic conversion by BMP-2 correlates with the expression of Bmpr-1a.

Authors:  Renjing Liu; Samantha L Ginn; Monkol Lek; Kathryn N North; Ian E Alexander; David G Little; Aaron Schindeler
Journal:  BMC Musculoskelet Disord       Date:  2009-05-15       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.